This New Coronavirus Test Can Detect The Disease In Five Minutes

Daniel Fowler
March 30, 2020

The test, which can deliver negative results in 13 minutes, will run on the company's ID NOW platform, according to a news release. But those tests, from the manufacturer Cepheid, are to be used mainly in hospitals. The portable point-of-care platform has been widely used to process quick strep throat and flu tests in physicians' offices, emergency rooms and urgent care clinics.

The company said it will be making ID NOW COVID-19 tests available next week with the ability to deliver 50,000 tests per day.

The test's small size means it can be deployed outside the "traditional four walls of a hospital in outbreak hotspots", Ford said, adding that Abbott is working with the FDA to send it to areas heavily hit by the virus.

Third, insert the mixture into the device, which uses molecular testing technologies to identify a small section of the virus' genome, and then replicate that portion until there's enough for detection.

Coronavirus outbreak: Trump says guidelines around social distancing extended to April 30
During the course of the Rose Garden briefing, reported deaths grew by several dozen and the number of cases by several thousand. Speaking earlier on Sunday, Dr.

At Sunday's Coronavirus Task Force Briefing at the White House, President Donald Trump announced that the Food and Drug Administration (FDA) had approved a new test for COVID-19 that could provide results in "as little as five minutes". ID NOW is the most widely available molecular point-of-care testing platform in the USA today, according to Abbott's website.

This comes a week after the company launched its Abbott m2000™ RealTime SARS-CoV-2 EUA test, which runs on the m2000™ RealTime System located in hospital and reference labs around the world.

The equipment can be set up nearly anywhere, but the company is working with its customers and the Trump administration to ensure the first cartridges used to perform the tests are sent to where they are most needed. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit. Combined with ID NOW, Abbott expects to produce about 5 million tests in April.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER